SCHEMBL12700752

SCHEMBL12700752

CCc1ccc(S(=O)(=O)NC(C)=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.62
DHFR P00374 1/20 0.62
TSHR P16473 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
ALDH1A1 P00352 5/20 0.61
HPGD P15428 2/20 0.61
MAPT P10636 1/20 0.55
EPHX2 P34913 1/20 0.54
PKM P14618 1/20 0.53
UCHL1 P09936 1/20 0.53
POLB P06746 1/20 0.53
KMT2A Q03164 3/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
MEN1 O00255 2/20 0.51
HSP90AA1 P07900 1/20 0.50
NPC1 O15118 1/20 0.50
HTT P42858 1/20 0.50
CA2 P00918 1/20 0.50
ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23512345 0.95 UCHL1 (0.61) SMN1; SMN2DHFRTSHRTDP1ALDH1A1
SCHEMBL13966984 0.86 SMN1; SMN2 (0.59) SMN1; SMN2DHFRTSHRTDP1ALDH1A1
SCHEMBL7596737 0.85 ALDH1A1 (0.61) SMN1; SMN2ALDH1A1HPGDMAPTPKM
SCHEMBL2928482 0.84 SMN1; SMN2 (0.66) SMN1; SMN2DHFRTSHRTDP1MAPT
SCHEMBL6859141 0.84 ALDH1A1 (0.59) ALDH1A1HPGDMAPTUCHL1KMT2A
SCHEMBL13648079 0.82 SMN1; SMN2 (0.59) SMN1; SMN2DHFRTSHRTDP1ALDH1A1
SCHEMBL13668104 0.81 SMN1; SMN2 (0.62) SMN1; SMN2DHFRTSHRTDP1EPHX2
SCHEMBL791784 0.81 L3MBTL1 (0.62) SMN1; SMN2DHFRTSHRTDP1ALDH1A1
SCHEMBL28291995 0.81 TSHR (0.67) SMN1; SMN2DHFRTSHRTDP1ALDH1A1
SCHEMBL10285030 0.80 ALDH1A1 (0.68) SMN1; SMN2DHFRTSHRTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120245174-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-09-27 US disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245174-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR BRAF, ARAF, RAF1 SMN1; SMN2 4746/4885DHFR 676/4885TSHR 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.